secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001104659-25-062837
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing
--------------------------------------------------------------------------------

- CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.
- CLR 225 (alpha-emitting, actinium-225) Phase 1 imaging and dose-escalation safety study in solid tumors planned for H2 2025, subject to financing.
- CLOVER-WaM study of iopofosine I 131 in Waldenström macroglobulinemia met primary endpoint with MRR of 58.2% (p<0.0001), ORR 83.6%, and 7.3% CR rate.
- No treatment-related deaths in CLOVER-WaM study; most common Grade 3+ TRAEs were thrombocytopenia (81.5%) and neutropenia (66.2%), all patients recovered.
- Proposed securities offering to fund operating expenses and initiate CLR 125 and CLR 225 clinical studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925062837/0001104659-25-062837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925062837/tm2519054d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-062837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer